Ultragenyx opens new gene therapy manufacturing facility in Bedford, MA

Ultragenyx Pharmaceutical officially opened its gene therapy manufacturing facility in Bedford, Massachusetts. The company has a large and diverse clinical pipeline of late-stage gene therapies for the potential treatment of rare genetic conditions. “Today we’re celebrating the result of several years’ worth of effort by hundreds of people, all driven by a single shared goal – to transform the lives of people living with rare disease,” said Dennis Huang, chief technical operations officer and executive vice president for gene therapy research and development at Ultragenyx. “Through this facility, Ultragenyx will develop and produce gene therapy treatments at greater scale than previously possible, which we believe will make these rare disease medicines more accessible to the people who need them.”